{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:32:26Z","timestamp":1777879946680,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To determine the frequency at which fluoroquinolones and aminoglycosides demonstrate in vitro activity against non-urinary, non-skin\/skin structure Pseudomonas aeruginosa isolates exhibiting decreased susceptibilities to one or more \u03b2-lactam agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\u03b2-lactam-non-susceptible P. aeruginosa isolates recovered from blood, bone, lower respiratory tract, pleural fluid, cerebrospinal fluid, or peritoneal fluid cultures between October 2010 and October 2014 were reviewed from four community hospitals within a single health-system. Only the first isolate per patient was included for analysis. The likelihood that each isolate was susceptible to a non-\u03b2-lactam antimicrobial was then determined and summarized within a combination antibiogram.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 179 P. aeruginosa isolates with decreased susceptibilities to one or more \u03b2-lactam agents were assessed. Because no appreciable differences in antimicrobial susceptibility profile were observed between hospitals, the isolates were evaluated in aggregate. Susceptibility rates for \u03b2-lactam monotherapy ranged from 34% to 75%. Aminoglycosides possessed increased antibacterial activity compared to fluoroquinolones. Tobramycin was the non-\u03b2-lactam most likely to expand antimicrobial coverage against \u03b2-lactam-non-susceptible P. aeruginosa with activity against 64%, 66%, and 65% of cefepime-, piperacillin-tazobactam-, and meropenem-non-susceptible isolates, respectively ( p\u2009&lt;\u20090.001 for all).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The results of this study support the use of aminoglycosides over fluoroquinolones for achieving optimal, empiric antimicrobial combination therapy for P. aeruginosa when dual antimicrobial therapy is clinically necessary. Future efforts aimed at optimizing combination therapy for P. aeruginosa should focus on systemic interventions that limit the selection of fluoroquinolones in combination with \u03b2-lactams to expand coverage based on local susceptibility rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2049936117725935","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T06:58:21Z","timestamp":1503471501000},"page":"165-170","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Results of a local combination therapy antibiogram for\n                    <i>Pseudomonas aeruginosa<\/i>\n                    isolates: is double worth the trouble?"],"prefix":"10.1177","volume":"4","author":[{"given":"Matthew","family":"Song","sequence":"first","affiliation":[{"name":"Norton Healthcare, Louisville, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Dilworth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Aurora St. Luke\u2019s Medical Center, Milwaukee, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Munson","sequence":"additional","affiliation":[{"name":"Marquette University, Milwaukee, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Davis","sequence":"additional","affiliation":[{"name":"Ascension - All Saints, Racine, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramy H.","family":"Elshaboury","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,8,23]]},"reference":[{"key":"bibr1-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.1.146"},{"key":"bibr2-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.2.462"},{"key":"bibr3-2049936117725935","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090360"},{"key":"bibr4-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"bibr5-2049936117725935","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1164\/ajrccm.153.5.8630626","volume":"153","author":"Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"bibr6-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1086\/377200"},{"key":"bibr7-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1306-1311.2005"},{"key":"bibr8-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis664"},{"key":"bibr9-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012413"},{"key":"bibr10-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1086\/500319"},{"key":"bibr11-2049936117725935","volume-title":"FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together","author":"US Food &amp; Drug Administration","year":"2016"},{"key":"bibr12-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000275389.31974.22"},{"key":"bibr13-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181e96b91"},{"key":"bibr14-2049936117725935","first-page":"413","volume":"27","author":"Mizuta M","year":"2006","journal-title":"Infection Control"},{"key":"bibr15-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1086\/650446"},{"key":"bibr16-2049936117725935","doi-asserted-by":"publisher","DOI":"10.3844\/ajidsp.2014.88.94"},{"key":"bibr17-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215586081."},{"key":"bibr18-2049936117725935","volume-title":"Healthcare cost and uitilization project","author":"HCUPnet","year":"2013"},{"key":"bibr19-2049936117725935","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Abbreviated identification of bacteria and yeast; approved guideline. CLSI document M35-A2. Wayne, PA: CLSI, 2008."},{"key":"bibr20-2049936117725935","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016","edition":"26"},{"key":"bibr21-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-16"},{"key":"bibr22-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02216-07"},{"key":"bibr23-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2005.002"},{"key":"bibr24-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1086\/338782"},{"key":"bibr25-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-09"},{"key":"bibr26-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.479-487.2005"},{"key":"bibr27-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01930.x"},{"key":"bibr28-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"bibr29-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38028.520995.63"},{"key":"bibr30-2049936117725935","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit223"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2049936117725935","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2049936117725935","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2049936117725935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:57:11Z","timestamp":1777593431000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2049936117725935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,23]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1177\/2049936117725935"],"URL":"https:\/\/doi.org\/10.1177\/2049936117725935","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,23]]}}}